Reappraisal of the management of Vogt–Koyanagi–Harada disease: sunset glow fundus is no more a fatality

• Published in: International ophthalmology Vol. 37; no. 6; pp. 1383 - 1395
• Main Authors: Herbort Jr, Carl P., Abu El Asrar, Ahmed M., Yamamoto, Joyce H., Pavésio, Carlos E., Gupta, Vishali, Khairallah, Moncef, Tugal-Tutkun, Ilknur, Soheilian, Masoud, Takeuchi, Masuru, Papadia, Marina
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.12.2017; Springer Nature B.V
• Subjects: Adrenal Cortex Hormones - therapeutic use; Choroiditis; Corticosteroids; Disease control; Drug Administration Schedule; Fundus Oculi; Humans; Immunosuppressive agents; Immunosuppressive Agents - therapeutic use; Inflammation; Medical treatment; Medicine; Medicine & Public Health; Ophthalmology; Retinal Diseases - prevention & control; Review; Reviews; Stroma; Therapy; Uveomeningoencephalitic Syndrome - drug therapy; Indocyanine green angiography; Vogt–Koyanagi–Harada disease; Immunosuppressive therapy; Granulomatous uveitis; Stromal choroiditis, autoimmune disease

Purpose Vogt–Koyanagi–Harada (VKH) disease is a primary autoimmune stromal choroiditis. Aim of the study was to gather a body of evidence from the literature and from experts that systemic corticosteroid combined with non-steroidal immunosuppressive therapy should become the standard of care in init...